Literature DB >> 9559812

Efficacy of sulfamethoxypyridazine in a murine model of Pneumocystis carinii pneumonia.

M S Bartlett1, M M Shaw, J W Smith, S R Meshnick.   

Abstract

Sulfamethoxazole is the component of co-trimoxazole responsible for its efficacy against Pneumocystis carinii pneumonia, but this drug is associated with frequent adverse effects. Sulfamethoxypyridazine is significantly more effective than sulfamethoxazole against a murine model of P. carinii and might be a candidate for testing in infected patients.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9559812      PMCID： PMC105571          DOI： 10.1128/AAC.42.4.934

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Severe reactions to long-acting sulfonamides. Erythema multiforme exudativum and lupus erythematosus following administration of sulfamethoxypyridazine and sulfadimethoxine.

Authors:  M L RALLISON; J O'BRIEN; R A GOOD
Journal:  Pediatrics       Date:  1961-12       Impact factor: 7.124

2.  Dihydropteroate synthase polymorphisms in Pneumocystis carinii.

Authors:  B R Lane; J C Ast; P A Hossler; D P Mindell; M S Bartlett; J W Smith; S R Meshnick
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

3.  Adverse reactions to sulfa drugs: implications for malaria chemotherapy.

Authors:  A Björkman; P A Phillips-Howard
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

4.  Inoculated mouse model of Pneumocystis carinii infection.

Authors:  M S Bartlett; S F Queener; M M Durkin; M A Shaw; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

5.  Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.

Authors:  Y L Hong; P Hossler; M Bartlett; S Queener; J Smith; S Meshnick
Journal:  J Eukaryot Microbiol       Date:  1996 Sep-Oct       Impact factor: 3.346

6.  [Pharmacokinetic model studies on the rat. The single-chamber model of the organism].

Authors:  K F Funk
Journal:  Acta Biol Med Ger       Date:  1970

Review 7.  Trimethoprim/sulfamethoxazole desensitization.

Authors:  L M Cortese; D M Soucy; T P Endy
Journal:  Ann Pharmacother       Date:  1996-02       Impact factor: 3.154

Review 8.  Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Authors:  R J Simonds; W T Hughes; J Feinberg; T R Navin
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

9.  The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy.

Authors:  S Kunz; U Junker; J Blaser; B Joos; B Meyer; O Zak; T O'Reilly
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.

Authors:  P D Walzer; J Foy; P Steele; C K Kim; M White; R S Klein; B A Otter; C Allegra
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
View more
  3 in total

1.  In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.

Authors:  Javier Afeltra; Jacques F G M Meis; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Bladder catheterization increases susceptibility to infection that can be prevented by prophylactic antibiotic treatment.

Authors:  Matthieu Rousseau; H M Sharon Goh; Sarah Holec; Matthew L Albert; Rohan Bh Williams; Molly A Ingersoll; Kimberly A Kline
Journal:  JCI Insight       Date:  2016-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.